Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
MWN-AI** Summary
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is set to advance its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, amid a growing interest in IL-6 therapeutics, highlighted by Novartis' recent $1.4 billion acquisition of Tourmaline Bio. The company plans to seek non-dilutive funding for TZLS-501's development while maintaining focus on its lead program, foralumab.
TZLS-501 targets both membrane-bound and soluble forms of IL-6R, a key player in mediating inflammatory responses linked to various diseases, such as rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), and systemic lupus erythematosus. By blocking IL-6R signaling and reducing circulating IL-6 cytokines, TZLS-501 aims to deliver significant therapeutic benefits for managing acute and chronic inflammation.
Ivor Elrifi, CEO of Tiziana, emphasized the increasing value of IL-6 therapies, particularly in light of recent market developments. He expressed enthusiasm for TZLS-501’s unique ability to address both forms of IL-6 signaling, which positions it as a potent treatment option for inflammatory conditions. This dual action includes the potential to function both alone and in combination with foralumab, as well as other anti-inflammatory and anti-infective agents.
Foralumab, Tiziana’s primary candidate, is the only fully human anti-CD3 monoclonal antibody being evaluated in patients with non-active secondary progressive multiple sclerosis, having produced positive clinical responses. With innovative drug delivery technologies that facilitate alternative routes of immunotherapy, Tiziana is well-positioned to make strides in developing effective treatments while expanding its pipeline.
For additional information, Tiziana Life Sciences’ website offers insights into its therapies and ongoing research initiatives.
MWN-AI** Analysis
Tiziana Life Sciences (Nasdaq: TLSA) is advancing its fully human monoclonal antibody, TZLS-501, which targets the IL-6 receptor. This strategic move is buoyed by the growing validation of IL-6 therapies, underscored by the recent $1.4 billion acquisition of Tourmaline Bio by Novartis. Tiziana's dual-action approach of blocking both membrane-bound and soluble IL-6 receptors positions TZLS-501 as a promising treatment across various inflammatory diseases, including rheumatoid arthritis, acute respiratory distress syndrome, and idiopathic pulmonary fibrosis.
The current market dynamics favor companies focusing on inflammation-related therapies, particularly with Novartis’ acquisition indicating heightened interest and investment in this space. Tiziana plans to leverage non-dilutive funding strategies, ensuring that resources are allocated effectively—advancing TZLS-501 while keeping the focus on its lead candidate, intranasal foralumab.
Investors should take note of Tiziana's unique market positioning. The dual mechanism of TZLS-501 could streamline development pathways potentially leading to faster clinical results. Additionally, the opportunity for combination therapies with foralumab and other anti-inflammatory agents could enhance the marketability of TZLS-501, expanding its therapeutic applications.
Given these developments, Tiziana's stock may present a compelling investment opportunity. The successful execution of its strategy to develop TZLS-501 alongside foralumab could lead to increased shareholder value, particularly if clinical trials yield positive results.
As the company navigates this critical phase, monitoring trial outcomes and funding achievements will be essential. While the biopharmaceutical landscape remains inherently volatile, Tiziana’s strategic focus could position it advantageously within a booming market for innovative treatments targeting inflammatory conditions. Therefore, investors might consider establishing or increasing positions in Tiziana during this pivotal development stage.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.
TZLS-501 is a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody (mAb) targeting both the membrane-bound and soluble forms of IL-6R. This dual mechanism of action not only blocks IL-6R signaling but also reduces circulating IL-6 cytokines, which are recognized drivers of inflammation, lung damage, and chronic fibrosis. Tiziana sees potential to develop TZLS-501 as a monotherapy, or in combination with its lead candidate, foralumab, as well as with other anti-inflammatory and anti-infective agents.
The recent acquisition by Novartis further validates the importance of IL-6 therapeutics. Tiziana believes this an opportune time for the parallel advancement of TZLS-501. Accordingly, Tiziana will pursue development of TZLS-501, while not diverting resources or focus from ongoing clinical trials with foralumab.
Excessive IL-6 signaling plays a central role in multiple diseases, including rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), systemic lupus erythematosus, and various cancers. By reducing both receptor-mediated signaling and circulating cytokine burden, TZLS-501 may offer therapeutic advantages in managing these acute and chronic inflammatory conditions.
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented, “Novartis’ recent acquisition of Tourmaline demonstrates how IL-6 therapy is increasingly valued in treating systemic inflammation and related diseases. While intranasal foralumab remains our lead program and primary focus, we are reviewing development opportunities for TZLS-501 as a complementary asset. Our fully human IL-6 mAb has always been an exciting asset. With recent market developments, we feel it is an opportune time to explore TZLS-501’s development. Its unique ability to address both membrane-bound and soluble IL-6 signaling, positions it as a potentially powerful therapy for acute and chronic inflammatory conditions.”
About TZLS-501
TZLS-501, a fully human mAb, was licensed from Novimmune, SA, (Geneva, CH) in 2017. IL-6 is a cytokine that binds to its receptor subunit IL-6R? on the cell membrane, and is a major determinant in priming of pathogenic T cells to produce an inflammatory response. The receptor IL-6R? can be shed in soluble form, sIL6R?, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this complex mediates pro-inflammatory effects underlying inflammatory diseases. TZLS-501 acts via a dual mechanism by inhibiting IL-6R signaling and depleting circulating levels of IL-6.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program ( NCT06802328 ) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis ( NCT06292923 ).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. [1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com .
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ**
How does Tiziana Life Sciences plc TLSA plan to finance the development of TZLS-501 without diluting shareholder equity?
What specific conditions does Tiziana Life Sciences plc TLSA intend to target with TZLS-501, given its dual mechanism of action against IL-6R signaling?
In what ways does Tiziana Life Sciences plc TLSA anticipate that TZLS-501 will complement its lead program, foralumab, in treating inflammatory diseases?
Considering the recent acquisition of Tourmaline Bio by Novartis, how does Tiziana Life Sciences plc TLSA view the competitive landscape for IL-6 therapeutics moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about Tiziana Life Sciences plc (NASDAQ: TLSA).
NASDAQ: TLSA
TLSA Trading
-4.69% G/L:
$1.22 Last:
67,692 Volume:
$1.27 Open:
